DPV-001

Phase 1Biologic

PProvidence Health & Services

DPV-001 is one of 3 biologic programs targeting Cancer of the Head and Neck. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cancer of the Head and NeckActive, not recruiting

Cancer of the Head and NeckPhase 1

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Cancer of the Head and Neck

#DrugCompanyPhaseTrials

INCMGA00012

Incyte

Phase 1

1 2

INCAGN01876

IIncyte Biosciences International Sàrl

Phase 1

1 3

DPV-001

PProvidence Health & Services

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Active, not recruiting

Cancer of the Head and Neck

NCT04470024

Clinical

Trials by Indication[1]

Cancer of the Head and Neck1 trial

A Phase Ib Study of Multivalent Autophagosome Vaccine, With or Without GITR Agonist, With Sequenced Checkpoint Inhibition (Anti-PD-1) - Immunotherapy Trio in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Active, not recruiting·PProvidence Health & Services·Phase 1·NCT04470024·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DPV-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DPV-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DPV-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Providence Health & Services company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: PProvidence Health & Services

DPV-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Cancer of the Head and Neck1 trial

References

Drug Info

Quick Facts

Related News